| Name | Title | Contact Details |
|---|
Med ISP is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innovus Pharma, headquartered in La Jolla, California, is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.
Goldfish Swim School was founded in 2005 by husband and wife team Chris and Jenny McCuiston. Chris and Jenny took a concept that they formulated with nearly two years of research, and cultivated a business that provides results in the learn-to-swim environment that you simply can`t find anywhere else. Their proprietary curriculum and systems were developed after traveling the country in search of the “best practices” to teach babies and young children how to swim. The first school, in Birmingham, Michigan, opened in 2006, and quickly saw success. Opening its doors with over 500 students at inception, Goldfish currently teaches more than 70,000 students per month across the franchise system. At the beginning of 2008, it made sense to begin the franchising process. As of early 2017, we are currently in the process of expanding franchise opportunities throughout the country and internationally, with over 80 schools open or in development in more than 23 states and Canada.
BG Medicine, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Waltham, MA. To find more information about BG Medicine, Inc., please visit www.bg-medicine.com
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.